AR094287A1 - Metodos y composiciones para administracion de oxibutinina - Google Patents

Metodos y composiciones para administracion de oxibutinina

Info

Publication number
AR094287A1
AR094287A1 ARP130105037A ARP130105037A AR094287A1 AR 094287 A1 AR094287 A1 AR 094287A1 AR P130105037 A ARP130105037 A AR P130105037A AR P130105037 A ARP130105037 A AR P130105037A AR 094287 A1 AR094287 A1 AR 094287A1
Authority
AR
Argentina
Prior art keywords
oxybutynin
oxibutinine
administration
compositions
methods
Prior art date
Application number
ARP130105037A
Other languages
English (en)
Inventor
a byron David
Fleming Scott
Cook Robert
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/728,706 external-priority patent/US9119777B2/en
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of AR094287A1 publication Critical patent/AR094287A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un método para tratar la enfermedad pulmonar que comprende administrar directamente a los pulmones de un paciente una cantidad terapéuticamente efectiva de oxibutinina en combinación con uno o más agentes farmacéuticamente efectivos. Reivindicación 6: El método de acuerdo con la reivindicación 1, en donde la oxibutinina comprende xinafoato de oxibutinina. Reivindicación 21: El método de acuerdo con la reivindicación 1, en donde la oxibutinina y el agente farmacéuticamente activo se administran usando un inhalador de polvo seco (DPI) o un inhalador de de dosis medida (MDI) o un nebulizador de líquidos.
ARP130105037A 2012-12-27 2013-12-27 Metodos y composiciones para administracion de oxibutinina AR094287A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/728,706 US9119777B2 (en) 2008-05-30 2012-12-27 Methods and compositions for administration of oxybutynin

Publications (1)

Publication Number Publication Date
AR094287A1 true AR094287A1 (es) 2015-07-22

Family

ID=51021931

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130105037A AR094287A1 (es) 2012-12-27 2013-12-27 Metodos y composiciones para administracion de oxibutinina

Country Status (15)

Country Link
EP (1) EP2938329A4 (es)
JP (1) JP2016504358A (es)
KR (1) KR20150100902A (es)
CN (1) CN104955444A (es)
AR (1) AR094287A1 (es)
AU (1) AU2013368298B2 (es)
BR (1) BR112015015421A2 (es)
CA (1) CA2895955A1 (es)
EA (1) EA201591218A1 (es)
HK (2) HK1215396A1 (es)
IL (1) IL239623A0 (es)
MX (1) MX2015008333A (es)
NZ (1) NZ628479A (es)
UY (1) UY35230A (es)
WO (1) WO2014105446A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3421049B1 (en) * 2016-02-25 2020-07-29 Hisamitsu Pharmaceutical Co., Inc. Liquid external preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767877B2 (en) * 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
BR0315258A (pt) * 2002-10-29 2005-08-23 Pharmacia & Upjohn Co Llc Compostos de amÈnio quaternário
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
WO2006047427A1 (en) * 2004-10-25 2006-05-04 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
CN102448309A (zh) * 2009-06-16 2012-05-09 谭文 左旋(r)班布特罗在制备治疗呼吸性疾病的吸入性药物制剂和药物组合中的应用
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
EP2552424B1 (en) * 2010-04-01 2018-05-09 Chiesi Farmaceutici S.p.A. Process for preparing carrier particles for dry powders for inhalation
WO2012047674A2 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation

Also Published As

Publication number Publication date
NZ628479A (en) 2016-06-24
HK1216843A1 (zh) 2016-12-09
UY35230A (es) 2015-01-30
EA201591218A1 (ru) 2015-11-30
AU2013368298B2 (en) 2016-08-11
EP2938329A4 (en) 2016-08-10
WO2014105446A1 (en) 2014-07-03
HK1215396A1 (zh) 2016-08-26
CN104955444A (zh) 2015-09-30
JP2016504358A (ja) 2016-02-12
CA2895955A1 (en) 2014-07-03
EP2938329A1 (en) 2015-11-04
AU2013368298A1 (en) 2015-07-02
BR112015015421A2 (pt) 2017-07-11
KR20150100902A (ko) 2015-09-02
MX2015008333A (es) 2015-11-09
IL239623A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
CL2009000601A1 (es) Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis.
MX2016004316A (es) Inhalador de polvo seco.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CU20110100A7 (es) Tratamiento de pirfenidona para pacientes con función hepática atípica
JP2015513309A5 (es)
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
PE20091672A1 (es) Nueva dosificacion y formulacion
CO2017008395A2 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol
NI201400139A (es) Nueva forma de dosificación y formulación de abediterol
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
DOP2014000269A (es) Nueva dosificación y formulación
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
ES2525451T3 (es) Uso de óxido nitroso inhalado para prevenir el dolor neuropático inducido por sales de platino
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
BR112015027247A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina
BR112022003687A2 (pt) Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina
JP2015533131A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure